Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

NCT06684522 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06684522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06684522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Recruiting
Start date
December 18, 2025
Completion date
June 30, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eyelid dermatitis